Abstract:Background Patient-derived tumor xenograft models have been established and increasingly used for preclinical studies of targeted therapies in recent years. However, patient-derived non-small cell lung cancer (NSCLC) xenograft mouse models are relatively few in number and are limited in their degree of genetic characterization and validation. In this study, we aimed to establish a variety of patient-derived NSCLC models and characterize these for common genetic aberrations to provide more informative models for preclinical drug efficacy testing. Methods NSCLC tissues from thirty-one patients were collected and implanted into immunodeficient mice. Established xenograft models were characterized for common genetic aberrations, including detection of gene mutations within EGFR and KRAS, and genetic amplification of FGFR1 and cMET . Finally, gefitinib anti-tumor efficacy was tested in these patient-derived NSCLC xenograft models. Results Ten passable patient-derived NSCLC xenograft models were established by implantation of NSCLC specimens of thirty-one patients into immunodeficient mice. Genetic aberrations were detected in six of the models, including one model with an EGFR activating mutation (Exon19 Del), one model with KRAS mutation, one model with both KRAS mutation and cMET gene amplification, and three models with FGFR1 amplification. Anti-tumor efficacy studies using gefitinib demonstrated that the EGFR activating mutation model had superior sensitivity and that the KRAS mutation models were resistant to gefitinib. The range of gefitinib responses in the patient-derived NSCLC xenograft models were consistent with the results reported from clinical trials. Furthermore, we observed that patient-derived NSCLC models with FGFR1 gene amplification were insensitive to gefitinib treatment. Conclusions Ten patient-derived NSCLC xenograft models were established containing a variety of genetic aberrations including EGFR activating mutation, KRAS mutation, and FGFR 1 and cMET amplification. Gefitinib anti-tumor efficacy in these patient-derived NSCLC xenografts containing EGFR and KRAS mutation was consistent with the reported results from previous clinical trials. Thus, data from our panel of patient-derived NSCLC xenograft models confirms the utility of these models in furthering our understanding of this disease and aiding the development of personalized therapies for NSCLC patients.

Establishment and Characterization of Esophageal Squamous Cell Carcinoma Patient-Derived Xenograft Mouse Models for Preclinical Drug Discovery

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

Establishment of patient-derived esophageal squamous-cell carcinoma xenograft in mice and characteristics of signaling pathways related to pro-liferation in SCID mice

A method for establishing a patient-derived xenograft model to explore new therapeutic strategies for esophageal squamous cell carcinoma

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Establishment and Genomic Characterizations of Patient-Derived Esophageal Squamous Cell Carcinoma Xenograft Models Using Biopsies for Treatment Optimization

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

269. PATIENT-DERIVED TUMOR ORGANOIDS AND XENOGRAFTS AS BASIC AND PRECLINICAL TRANSLATIONAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MODELS

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenograft Models with Genetic Aberrations Within EGFR, KRAS and FGFR1: Useful Tools for Preclinical Studies of Targeted Therapies

Establishment of Primary Human Esophageal Xenografts: Rationale for Selection and Cancer Model

Preparation and Application of Patient-Derived Xenograft Mice Model of Colorectal Cancer

New Metabolic Alterations and A Predictive Marker Pipecolic Acid in Sera for Esophageal Squamous Cell Carcinoma

Establishment of human esophageal cancer xenograft model in immunocompetent mice and explorations of related immunological changes

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study

Establishment of patient derived non small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical …

Establishment and Clinical Significance of the Patient-Derived Xenograft Model of Colorectal Cancer

A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries

Anlotinib Combined with Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

Establishment and Characterization of a Patient-Derived Metastatic Extraskeletal Ewing Sarcoma Cell Line ES-ZSS-1